View in EDS HTML Full Text PDF Full Text

Effects of CYP2C19 genetic polymorphisms on the pharmacokinetics of lacosamide in Korean patients with epilepsy.

Saved in:
Bibliographic Details
Title: Effects of CYP2C19 genetic polymorphisms on the pharmacokinetics of lacosamide in Korean patients with epilepsy.
Authors: Ahn, Seon‐Jae (AUTHOR), Oh, Jaeseong (AUTHOR), Kim, Do‐Yong (AUTHOR), Son, Hyoshin (AUTHOR), Hwang, Sungeun (AUTHOR), Shin, Hye‐Rim (AUTHOR), Kim, Eun Young (AUTHOR), Lee, Han Sang (AUTHOR), Lee, Woo‐Jin (AUTHOR), Moon, Jangsup (AUTHOR), Lee, Soon‐Tae (AUTHOR), Jung, Keun‐Hwa (AUTHOR), Park, Kyung‐Il (AUTHOR), Jung, Ki‐Young (AUTHOR), Lee, SeungHwan (AUTHOR), Yu, Kyung‐Sang (AUTHOR), Chu, Kon (AUTHOR), Lee, Sang Kun (AUTHOR)
Source: Epilepsia (Series 4). Nov2022, Vol. 63 Issue 11, p2958-2969. 12p.
Subjects: Genetic polymorphisms, People with epilepsy, Koreans, Cytochrome P-450 CYP2C19, Single nucleotide polymorphisms
Abstract: Objective: Many pharmacokinetic studies of lacosamide (LCM) have been reported, but no large‐scale clinical study has been conducted on genetic polymorphisms that affect the metabolism of LCM. Therefore, we designed a pharmacogenetic study of LCM to explore the effect of genetic polymorphisms on serum LCM concentration. We evaluated the pharmacodynamic characteristics of LCM, including clinical efficacy and toxicity. Methods: Adult patients with epilepsy who received LCM at Seoul National University Hospital were enrolled. Blood samples were obtained from 115 patients taking LCM for more than 1 month with unchanged doses and were used to analyze the serum LCM concentration, the concentration/dose (C/D) ratio and the single nucleotide polymorphisms (SNPs) of the cytochrome P450 (CYP)2C9 and CYP2C19 genes. In addition, clinical information—including efficacy, toxicity, and concomitant drugs—was collected. Results: The serum LCM concentration showed a linear correlation with the daily dose (r =.66, p <.001). In genetic analysis, 43 patients (38.7%) were extensive metabolizers (EMs), 51 (45.9%) were intermediate metabolizers (IMs), and 17 (15.3%) were poor metabolizers (PMs). In the group comparison, mean serum concentrations and the C/D ratio showed significant differences between the three groups (p =.01 and p <.001, respectively). The C/D ratios of IM (27.78) and PM (35.6) were 13% and 39% higher than those of EM (25.58), respectively. In the pharmacodynamic subgroup analysis, patients in the ineffective LCM group had significantly lower serum concentrations (6.39 ± 3.25 vs. 8.44 ± 3.68 μg/ml, p =.024), whereas patients with adverse events had higher serum concentrations than those without adverse events (11.03 ± 4.32 vs. 7.4 ± 3.1 μg/ml, p <.001). Based on this, we suggest a reference range for LCM in the Korean population (6–9 μg/ml). Significance: Genetic polymorphisms of the CYP2C19 gene affect the serum LCM concentration. Because efficacy and toxicity are apparently related to serum LCM levels, the genetic phenotype of CYP2C19 should be considered when prescribing LCM for patients with epilepsy. [ABSTRACT FROM AUTHOR]
Copyright of Epilepsia (Series 4) is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 160176309
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Effects of CYP2C19 genetic polymorphisms on the pharmacokinetics of lacosamide in Korean patients with epilepsy.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Ahn%2C+Seon‐Jae%22&quot;&gt;Ahn, Seon‐Jae&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Oh%2C+Jaeseong%22&quot;&gt;Oh, Jaeseong&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Kim%2C+Do‐Yong%22&quot;&gt;Kim, Do‐Yong&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Son%2C+Hyoshin%22&quot;&gt;Son, Hyoshin&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Hwang%2C+Sungeun%22&quot;&gt;Hwang, Sungeun&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Shin%2C+Hye‐Rim%22&quot;&gt;Shin, Hye‐Rim&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Kim%2C+Eun+Young%22&quot;&gt;Kim, Eun Young&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Lee%2C+Han+Sang%22&quot;&gt;Lee, Han Sang&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Lee%2C+Woo‐Jin%22&quot;&gt;Lee, Woo‐Jin&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Moon%2C+Jangsup%22&quot;&gt;Moon, Jangsup&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Lee%2C+Soon‐Tae%22&quot;&gt;Lee, Soon‐Tae&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Jung%2C+Keun‐Hwa%22&quot;&gt;Jung, Keun‐Hwa&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Park%2C+Kyung‐Il%22&quot;&gt;Park, Kyung‐Il&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Jung%2C+Ki‐Young%22&quot;&gt;Jung, Ki‐Young&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Lee%2C+SeungHwan%22&quot;&gt;Lee, SeungHwan&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Yu%2C+Kyung‐Sang%22&quot;&gt;Yu, Kyung‐Sang&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Chu%2C+Kon%22&quot;&gt;Chu, Kon&lt;/searchLink&gt; (AUTHOR)&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Lee%2C+Sang+Kun%22&quot;&gt;Lee, Sang Kun&lt;/searchLink&gt; (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22Epilepsia+%28Series+4%29%22&quot;&gt;Epilepsia (Series 4)&lt;/searchLink&gt;. Nov2022, Vol. 63 Issue 11, p2958-2969. 12p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Genetic+polymorphisms%22&quot;&gt;Genetic polymorphisms&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22People+with+epilepsy%22&quot;&gt;People with epilepsy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Koreans%22&quot;&gt;Koreans&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Cytochrome+P-450+CYP2C19%22&quot;&gt;Cytochrome P-450 CYP2C19&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Single+nucleotide+polymorphisms%22&quot;&gt;Single nucleotide polymorphisms&lt;/searchLink&gt;
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Objective: Many pharmacokinetic studies of lacosamide (LCM) have been reported, but no large‐scale clinical study has been conducted on genetic polymorphisms that affect the metabolism of LCM. Therefore, we designed a pharmacogenetic study of LCM to explore the effect of genetic polymorphisms on serum LCM concentration. We evaluated the pharmacodynamic characteristics of LCM, including clinical efficacy and toxicity. Methods: Adult patients with epilepsy who received LCM at Seoul National University Hospital were enrolled. Blood samples were obtained from 115 patients taking LCM for more than 1 month with unchanged doses and were used to analyze the serum LCM concentration, the concentration/dose (C/D) ratio and the single nucleotide polymorphisms (SNPs) of the cytochrome P450 (CYP)2C9 and CYP2C19 genes. In addition, clinical information—including efficacy, toxicity, and concomitant drugs—was collected. Results: The serum LCM concentration showed a linear correlation with the daily dose (r =.66, p &lt;.001). In genetic analysis, 43 patients (38.7%) were extensive metabolizers (EMs), 51 (45.9%) were intermediate metabolizers (IMs), and 17 (15.3%) were poor metabolizers (PMs). In the group comparison, mean serum concentrations and the C/D ratio showed significant differences between the three groups (p =.01 and p &lt;.001, respectively). The C/D ratios of IM (27.78) and PM (35.6) were 13% and 39% higher than those of EM (25.58), respectively. In the pharmacodynamic subgroup analysis, patients in the ineffective LCM group had significantly lower serum concentrations (6.39 &#177; 3.25 vs. 8.44 &#177; 3.68 μg/ml, p =.024), whereas patients with adverse events had higher serum concentrations than those without adverse events (11.03 &#177; 4.32 vs. 7.4 &#177; 3.1 μg/ml, p &lt;.001). Based on this, we suggest a reference range for LCM in the Korean population (6–9 μg/ml). Significance: Genetic polymorphisms of the CYP2C19 gene affect the serum LCM concentration. Because efficacy and toxicity are apparently related to serum LCM levels, the genetic phenotype of CYP2C19 should be considered when prescribing LCM for patients with epilepsy. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of Epilepsia (Series 4) is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder&#39;s express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=160176309
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/epi.17399
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 12
        StartPage: 2958
    Subjects:
      – SubjectFull: Genetic polymorphisms
        Type: general
      – SubjectFull: People with epilepsy
        Type: general
      – SubjectFull: Koreans
        Type: general
      – SubjectFull: Cytochrome P-450 CYP2C19
        Type: general
      – SubjectFull: Single nucleotide polymorphisms
        Type: general
    Titles:
      – TitleFull: Effects of CYP2C19 genetic polymorphisms on the pharmacokinetics of lacosamide in Korean patients with epilepsy.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ahn, Seon‐Jae
      – PersonEntity:
          Name:
            NameFull: Oh, Jaeseong
      – PersonEntity:
          Name:
            NameFull: Kim, Do‐Yong
      – PersonEntity:
          Name:
            NameFull: Son, Hyoshin
      – PersonEntity:
          Name:
            NameFull: Hwang, Sungeun
      – PersonEntity:
          Name:
            NameFull: Shin, Hye‐Rim
      – PersonEntity:
          Name:
            NameFull: Kim, Eun Young
      – PersonEntity:
          Name:
            NameFull: Lee, Han Sang
      – PersonEntity:
          Name:
            NameFull: Lee, Woo‐Jin
      – PersonEntity:
          Name:
            NameFull: Moon, Jangsup
      – PersonEntity:
          Name:
            NameFull: Lee, Soon‐Tae
      – PersonEntity:
          Name:
            NameFull: Jung, Keun‐Hwa
      – PersonEntity:
          Name:
            NameFull: Park, Kyung‐Il
      – PersonEntity:
          Name:
            NameFull: Jung, Ki‐Young
      – PersonEntity:
          Name:
            NameFull: Lee, SeungHwan
      – PersonEntity:
          Name:
            NameFull: Yu, Kyung‐Sang
      – PersonEntity:
          Name:
            NameFull: Chu, Kon
      – PersonEntity:
          Name:
            NameFull: Lee, Sang Kun
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: Nov2022
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 00139580
          Numbering:
            – Type: volume
              Value: 63
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: Epilepsia (Series 4)
              Type: main
ResultId 1